The present invention relates to a topical composition for delivering API. In at least one embodiment, the composition comprises the pharmaceutically active ingredient, in particular ropivacaine, and/or a salt thereof at least one adhesive material and at least one backing material and wherein, after application of the topical composition to keratinous materials of a subject, a pharmaceutically effective amount of the pharmaceutically active ingredient, in particular ropivacaine, permeates into the subject for greater than 12 hours while the topical composition remains adhesive to the keratinous material. A method of making the topical composition, and a method of continuous treatment of pain using the topical composition are also disclosed. Furthermore, a topical composition delivering at least one pharmaceutically active ingredient or salts thereof comprising the at least one pharmaceutically active ingredient or salts thereof at least one adhesive material at least one backing material and at least one hydrophilic polymer in an amount ranging from 5% (w/w)-10% (w/w) wherein, after application of the topical composition to keratin material of a subject, the adhesivity of the topical composition is reduced while wearing, such that after 24 hours an external force no greater than 2.4 N is required to remove the topical composition from the keratin material.La présente invention concerne une composition pour voie topique visant à dispenser un principe pharmaceutiquement actif (API). Dans au moins un mode de réalisation, la composition comprend le principe pharmaceutiquement actif, en particulier la ropivacaïne et/ou un sel de cette dernière au moins un matériau adhésif et au moins un matériau de support la composition topique permettant, après application sur les substances kératiniques dun patient, quune quantité pharmaceutiquement efficace du principe pharmaceutiquement actif, en particulier la ropivacaïne, diffuse vers lintérieur du patient pendant plus de 12 h
